Feasibility of Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving 5-day chemotherapy rejimens

Not Applicable

• Conditions: Patients receiving multiple chemotherapy including highly or moderate emetogenic agents

• Registration Number: JPRN-UMIN000015386
• Lead Sponsor: ational cancer center hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-10-09
• Study Completion: 2016-04-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

Not provided

Exclusion Criteria

a)patients who had diabetes mellitus or past history of diabetes mellitus b)patients who take adrenaline beginning chemotherapy. c)patients who take barbituric acid beginning chemotherapy. d)patients who had received any chemotherapy. e)patients who take opioid. f)patients who have nausea or vomiting starting study. g)Active infectious diseases h)Severe complications i)history of hypersensitivity or allergy for study drugs or similar compounds. j)patients with clinically problematic, psycho-neurologic diseases k)pregnant, breastfeeding or expecting woman. l) patients with symptomatic brain metastasis m)patients with obstruction of gastrointestinal tract, for example ileus etc. n)patients who are disqualified by attending physicians o)patients with gastrointestinal cancer

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
feasibility

Secondary Outcome Measures

Name	Time	Method
To decide recommended dose.